Action Potential Venture CapitalWe are a small dedicated team that is backed by GlaxoSmithKline but remains firewalled from the company.
Who we are
APVC is a leading medical technology venture capital firm founded by GlaxoSmithKline in 2013. We invest around the world and take a hands-on role on the boards of start-ups advancing bioelectronic medicines and their enabling technologies.
We believe in the fundamental advantage of a diverse workplace and are committed to creating a fairer, more diverse healthcare investor and entrepreneurial community. Our commitment begins at APVC through the diversity of our investment team, and we extend this accountability to the companies we invest in.
What is Bioelectronic Medicine
Bioelectronic medicine is an emerging therapeutic field which leverages advances in hardware, computing and material science to regulate neural or cellular activity, and more effectively treat a range of chronic diseases.
One important therapeutic target for bioelectronic medicines is the nervous system which carries electrical impulses – or action potentials – that control virtually every organ or function in our bodies. The nervous system can be modulated to treat diseases through the targeted delivery of various forms of energy including electrical, electromagnetic, and acoustic energy.
Who we back
Who we are
Silicon Valley Startup Exo Secures $40M in Series B+ funding to Advance Handheld Medical Imaging
Cala Health Announces Continued Growth and Momentum with Clinical, Product Development, and Management Milestones to Support Cala Trio Therapy for the Treratment of Essential Tremor
Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in Patients With Drug Refractory Rheumatoid Arthritis